The 2026 Nobel Prize in Physiology or Medicine has been awarded to three researchers whose work revealed how individual nerve cells can be turned on or off, a discovery that reshaped the study of the brain and gave scientists a powerful new tool for investigating how neural circuits operate.
Karl Deisseroth, Peter Hegemann and Georg Nagel were named as this year's laureates on Monday, according to the announcement from Stockholm. The prize recognizes their investigations into light-gated ion channels and the field that grew out of that work, optogenetics, which allows researchers to control the activity of specific neurons with bursts of light.
The three men have built careers on different sides of the Atlantic, with appointments at universities in Germany and the United States. Deisseroth, 54, is a professor in the departments of bioengineering and psychiatry at Stanford University in California. Hegemann, 71, and Nagel, 73, are based at German institutions and have long been associated with the study of light-sensitive proteins in microorganisms.
Their combined contributions addressed a fundamental problem in neuroscience: how to influence the behavior of a single neuron without disturbing the thousands of others surrounding it. The Nobel committee praised the laureates for their research into the mechanisms the brain relies on to switch the activity of individual nerve cells on or off.
Optogenetics, the technique that emerged from their discoveries, works by introducing light-sensitive proteins into nerve cells. Once in place, these channels respond to specific wavelengths of light, allowing researchers to trigger or silence electrical signals in targeted neurons with remarkable precision. The approach has been compared to having a remote control for the brain's wiring, though scientists are careful to note that its applications in humans remain largely experimental.
The foundation for this technology came from the study of algae and other simple organisms that use light to regulate their internal chemistry. Hegemann and Nagel were among the researchers who identified and characterized channelrhodopsin, a protein that opens in response to light and lets ions flow across a cell membrane. Deisseroth later recognized that this microbial protein could be inserted into mammalian neurons, where it would make those cells responsive to light as well.
That insight transformed optogenetics from a laboratory curiosity into a mainstream method. Today it is used in thousands of laboratories worldwide to explore questions ranging from how memories are stored to how the brain controls movement, appetite and emotion. By activating or suppressing specific groups of neurons, scientists can observe the consequences in living animals and begin to map the circuits responsible for particular behaviors.
The technique has also opened new avenues for understanding and potentially treating neurological and psychiatric conditions. Researchers have used optogenetic methods in animal models to probe the circuitry involved in Parkinson's disease, depression, anxiety and addiction, among other disorders. While the technique itself is not yet a routine therapy, it has helped identify which cells and pathways might be worth targeting with future treatments.
For Deisseroth, the award adds to a lengthy list of recognitions. In April 2023, he received a Japan Prize in the life sciences field, an honor presented during a ceremony in Tokyo. Colleagues have described him as both a physician and an engineer, a combination that allowed him to bridge the gap between molecular biology and clinical psychiatry.
Hegemann and Nagel, meanwhile, are credited with the painstaking biochemical work that made the field possible. Their research on light-gated ion channels in microorganisms provided the raw material that others would adapt for use in animals. Without a detailed understanding of how these proteins function, the later applications in neuroscience would have been difficult, if not impossible, to develop.
The Nobel Assembly's decision highlights a broader trend in modern science: major advances increasingly depend on the fusion of disciplines that were once separate. Optogenetics sits at the intersection of physics, genetics, microbiology and medicine, and its development required collaboration across fields and continents. The three laureates represent different strands of that effort, each essential to the final result.
The prize announcement marks the beginning of this year's Nobel season, with awards in physics, chemistry, literature, peace and economics to follow in the coming days. The medicine prize is traditionally the first to be revealed, and it often sets the tone for the week by drawing attention to research that may have profound implications for human health.
Millions of people live with conditions rooted in the brain's electrical circuitry, from epilepsy to chronic pain to mood disorders. The work honored this year has not yet produced a cure for any of them, but it has given scientists a means of asking more precise questions than ever before. By learning how to switch individual cells on and off, researchers have gained a way to test theories about brain function that were once beyond the reach of experiment.
For the laureates, the recognition is a capstone on decades of investigation. For the field, it is a signal that the tools of optogenetics have become indispensable to the study of the nervous system. And for patients and families waiting for better treatments, it is a reminder that the path from basic discovery to clinical benefit is long, but that it often begins with a single, well-aimed beam of light.
(0)